Marta Kjellberg

BGI-HL OHA Lab inaugurated in Harbin, initiating colorectal cancer risk assessment for 800,000

2 min read

BGI-HL OHA Lab inaugurated in Harbin, initiating colorectal cancer risk assessment for 800,000

On May 10, 2024, the BGI-Heilongjiang Omics Health Axis Intelligent Laboratory (BGI-HL OHA Intelligent Laboratory) was inaugurated in Harbin, Heilongjiang province, China, marking...

Read More

DDRC Agilus Diagnostics, a unit of Agilus Diagnostics Ltd. Launches Largest 24×7 Reference Laboratory and Wellness Center in Kottayam

2 min read

DDRC Agilus Diagnostics, a unit of Agilus Diagnostics Ltd. Launches Largest 24×7 Reference Laboratory and Wellness Center in Kottayam

DDRC Agilus Diagnostics (a subsidiary of Agilus Diagnostics Limited), today announced the launch of their regional wellness...

Read More

TreeFrog Presents Data from Its Parkinson’s Cell Therapy Program

2 min read

TreeFrog Presents Data from Its Parkinson’s Cell Therapy Program

TreeFrog Therapeutics, a cell therapy development company with its leading Parkinson’s disease program, is presenting for the...

Read More

EVERSANA Completes Integration of Healthware Group and Strengthens Its Global Agency Network EVERSANA INTOUCH With Addition of New Full-Service Affiliate

2 min read

EVERSANA Completes Integration of Healthware Group and Strengthens Its Global Agency Network EVERSANA INTOUCH With Addition of New Full-Service Affiliate

EVERSANA, a leading provider of global commercial services to the life sciences industry, today unveiled a new...

Read More

China Medical University Hospital (CMUH) Launches “Intelligent Microbiome Evaluation- iME” to Detect Intestinal Bad Bacteria and Empowers Personalized Gut Health

2 min read

China Medical University Hospital (CMUH) Launches “Intelligent Microbiome Evaluation- iME” to Detect Intestinal Bad Bacteria and Empowers Personalized Gut Health

Gastrointestinal (GI) examinations can be invasive or non-invasive. Stool tests (non-invasive) can be associated with limitations such...

Read More

eXeX & AdventHealth Surgery Center Innovation Tower Pioneer Use of Apple Vision Pro in Joint Replacement Surgery

2 min read

eXeX & AdventHealth Surgery Center Innovation Tower Pioneer Use of Apple Vision Pro in Joint Replacement Surgery

eXeX, a leader in artificial intelligence enhanced surgical logistics software, has achieved a world first by successfully...

Read More

Venus Remedies secures regulatory approvals for three key oncology drugs in Ukraine

2 min read

Venus Remedies secures regulatory approvals for three key oncology drugs in Ukraine

Venus Remedies, one of India’s leading exporters of generic medicines in critical care segments, has further expanded...

Read More

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada

2 min read

Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada

Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and...

Read More

Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology

2 min read

Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology

Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) today announced that it has commenced sales...

Read More

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

2 min read

Ocugen, Inc. Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 1 of Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410

Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing...

Read More